177 related articles for article (PubMed ID: 16705407)
21. Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations.
Simoneau AR; Spruck CH; Gonzalez-Zulueta M; Gonzalgo ML; Chan MF; Tsai YC; Dean M; Steven K; Horn T; Jones PA
Cancer Res; 1996 Nov; 56(21):5039-43. PubMed ID: 8895761
[TBL] [Abstract][Full Text] [Related]
22. Loss of heterozygosity, a frequent but a non-exclusive mechanism responsible for HLA dysregulation in non-Hodgkin's lymphomas.
Drénou B; Tilanus M; Semana G; Alizadeh M; Birebent B; Grosset JM; Dias P; van Wichen D; Arts Y; De Santis D; Fauchet R; Amiot L
Br J Haematol; 2004 Oct; 127(1):40-9. PubMed ID: 15384976
[TBL] [Abstract][Full Text] [Related]
23. Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors.
Jiménez P; Cantón J; Collado A; Cabrera T; Serrano A; Real LM; García A; Ruiz-Cabello F; Garrido F
Int J Cancer; 1999 Sep; 83(1):91-7. PubMed ID: 10449614
[TBL] [Abstract][Full Text] [Related]
24. Detection of loss of heterozygosity in the p53 tumor-suppressor gene with PCR in the urine of patients with bladder cancer.
Friedrich MG; Erbersdobler A; Schwaibold H; Conrad S; Huland E; Huland H
J Urol; 2000 Mar; 163(3):1039-42. PubMed ID: 10688045
[TBL] [Abstract][Full Text] [Related]
25. Involvement of the chaperone tapasin in HLA-B44 allelic losses in colorectal tumors.
Cabrera CM; López-Nevot MA; Jiménez P; Garrido F
Int J Cancer; 2005 Feb; 113(4):611-8. PubMed ID: 15455354
[TBL] [Abstract][Full Text] [Related]
26. Human bladder cancers and normal bladder mucosa present the same hot spot of heterozygous chromosome-9 deletion.
Baud E; Catilina P; Boiteux JP; Bignon YJ
Int J Cancer; 1998 Sep; 77(6):821-4. PubMed ID: 9714047
[TBL] [Abstract][Full Text] [Related]
27. Study of allelic losses on 3p, 6q, and 17p in human urothelial cancer.
Bernués M; Casadevall C; Caballín MR; Miró R; Ejarque MJ; Chéchile G; Gelabert A; Egozcue J
Cancer Genet Cytogenet; 1999 Jul; 112(1):42-5. PubMed ID: 10432934
[TBL] [Abstract][Full Text] [Related]
28. [Loss of heterozygosity of tumor suppressor genes at chromosome 3p in transitional cell carcinoma of urinary bladder].
Xiao Z; Zhang J; Zheng S; Li C; He Z; Cheng S; Gao Y
Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(20):1375-7. PubMed ID: 12509916
[TBL] [Abstract][Full Text] [Related]
29. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
Singh RB; Amare Kadam PS
Urol Oncol; 2013 Oct; 31(7):1333-42. PubMed ID: 21962529
[TBL] [Abstract][Full Text] [Related]
30. Allelotype of human bladder cancer.
Knowles MA; Elder PA; Williamson M; Cairns JP; Shaw ME; Law MG
Cancer Res; 1994 Jan; 54(2):531-8. PubMed ID: 8275491
[TBL] [Abstract][Full Text] [Related]
31. Loss of heterozygosity on chromosome 6p21.2 as a potential marker for recurrence after radiotherapy of human cervical cancer.
Harima Y; Harima K; Sawada S; Tanaka Y; Arita S; Ohnishi T
Clin Cancer Res; 2000 Mar; 6(3):1079-85. PubMed ID: 10741737
[TBL] [Abstract][Full Text] [Related]
32. Clonal origin of lymph node metastases in bladder carcinoma.
Jones TD; Carr MD; Eble JN; Wang M; Lopez-Beltran A; Cheng L
Cancer; 2005 Nov; 104(9):1901-10. PubMed ID: 16196038
[TBL] [Abstract][Full Text] [Related]
33. Microsatellite alterations in human bladder cancer: detection of tumor cells in urine sediment and tumor tissue.
Berger AP; Parson W; Stenzl A; Steiner H; Bartsch G; Klocker H
Eur Urol; 2002 May; 41(5):532-9. PubMed ID: 12074795
[TBL] [Abstract][Full Text] [Related]
34. Frequent HLA class I loss is an early event in cervical carcinogenesis.
Vermeulen CF; Jordanova ES; Zomerdijk-Nooijen YA; ter Haar NT; Peters AA; Fleuren GJ
Hum Immunol; 2005 Nov; 66(11):1167-73. PubMed ID: 16571417
[TBL] [Abstract][Full Text] [Related]
35. High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity.
Rodriguez T; Méndez R; Roberts CH; Ruiz-Cabello F; Dodi IA; López Nevot MA; Paco L; Maleno I; Marsh SG; Pawelec G; Garrido F
Cancer Immunol Immunother; 2005 Feb; 54(2):141-8. PubMed ID: 15592718
[TBL] [Abstract][Full Text] [Related]
36. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma.
Cheng L; Jones TD; McCarthy RP; Eble JN; Wang M; MacLennan GT; Lopez-Beltran A; Yang XJ; Koch MO; Zhang S; Pan CX; Baldridge LA
Am J Pathol; 2005 May; 166(5):1533-9. PubMed ID: 15855652
[TBL] [Abstract][Full Text] [Related]
37. Allelic changes at multiple regions of chromosome 5 are associated with progression of urinary bladder cancer.
von Knobloch R; Bugert P; Jauch A; Kälble T; Kovacs G
J Pathol; 2000 Feb; 190(2):163-8. PubMed ID: 10657014
[TBL] [Abstract][Full Text] [Related]
38. Frequency and genetic basis of MHC, beta-2-microglobulin and MEMO-1 loss of heterozygosity in sporadic breast cancer.
McEvoy CR; Seshadri R; Morley AA; Firgaira FA
Tissue Antigens; 2002 Sep; 60(3):235-43. PubMed ID: 12445306
[TBL] [Abstract][Full Text] [Related]
39. Molecular genetic alterations in the laser-capture-microdissected stroma adjacent to bladder carcinoma.
Paterson RF; Ulbright TM; MacLennan GT; Zhang S; Pan CX; Sweeney CJ; Moore CR; Foster RS; Koch MO; Eble JN; Cheng L
Cancer; 2003 Nov; 98(9):1830-6. PubMed ID: 14584063
[TBL] [Abstract][Full Text] [Related]
40. Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells.
Carretero R; Cabrera T; Gil H; Saenz-Lopez P; Maleno I; Aptsiauri N; Cozar JM; Garrido F
Int J Cancer; 2011 Aug; 129(4):839-46. PubMed ID: 20957629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
